Norway, sisiyasatin ang kaso ng blood clot sa mga nabakunahan ng AstraZeneca vaccine

Naitala naman Norwegian health officials ang tatlo pang kaso ng blood clots o brain haemorrhages sa ilang nakababatang adult na tumanggap ng AstraZeneca COVID-19 jab, bagamat sinabi ng awtoridad na hindi pa nila masasabi kung vaccinerelated ang nangyari.

Sinabi ng Norwegian Medicines Agency na ilang katulad na insidente ang naiulat sa ibang European countries. Bagamat wala pang patunay na konektado ito sa bakuna, sinuman na 50anyos pababa na narakanas ng hindi magandang pakiramdam at nag-develop ng “large blue patches” matapos mabakunahan ay dapat humingi ng medical attention.

Sinabi na ng World Health Organization na walang “causal link had been established between the vaccine and blood clotting” matapos suspindehin ng Denmark, Norway at Iceland nitong Huwebes ang paggamit ng Bakuna hinggil sa pangamba sa mga pasyente na nag-develop ng post-jab blood clots.

Ilan pang bansa ang pansamantala ring inihinto ang paggamit ng bakuna mula sa isang batch. Denmark ang unang nag-anunsiyo ng pagsuspinde sa paggamit ng AstraZeneca vaccine, bagamat binigyang-diin nito na ang hakbang ay precautionary lamang at “it has not been determined, at the time being, that there is a link between the vaccine and the blood clots.”

Nitong Sabado, sinabi ng Norwegian Medicines Agency na “received several adverse event reports about younger vaccinated people with bleeding under the skin (tiny dots and /or larger blue patches) after coronavirus vaccination.” “This is serious and can be a sign of reduced blood platelet counts,” anila.

“Today, we received three more reports of severe cases of blood clots or brain haemorrhages in younger people who have received the AstraZeneca vaccine. These are now receiving hospital treatment,” dagdag pa nito.

Sinabi naman ni Geir Bukholm, director ng Infection Control and Environmental Health sa Norwegian Institute of Public Health, na matapos ang desisyon na suspindehin ang paggamit ng bakuna, “it was now the Norwegian Medicines Agency’s role to follow up on these suspected side effects and take the necessary measures.”

Dinepensahan naman ng AstraZeneca, isang Anglo-Swedish company na bumuo ng bakuna kasama ang Oxford University, ang kaligtasan ng kanilang bakuna.

“The safety of the vaccine has been extensively studied in phase III clinical trials and peer-reviewed data confirms the vaccine has been generally well tolerated,” pahayag ng spokesman sa AFP.